Cullinan Oncology, Inc. stock is down -7.98% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 14.29% of the previous 14 December’s closed higher than November. In the last 1 Unusual Options Trades, there were 1 PUT.
Cullinan Oncology Inc. focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.